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the microvascular architecture of LTS when clinicopatholog-
ical evidence of cutaneous GVHD is absent. Microvascular 
remodeling as observed during chronic GVHD recovers com-
pletely after resolution of chronic cutaneous GVHD. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Graft-versus-host disease (GVHD) is a major compli-
cation of allogeneic hematopoietic stem cell transplanta-
tion (HSCT). Its acute or chronic form is the main cause 
of nonrelapse morbidity and mortality both as a direct 
complication (e.g. bronchiolitis obliterans) or via associ-
ated immunodeficiency and susceptibility to severe in-
fections  [1–3] .
 Contrary to some expectations, the incidence of 
GVHD did not significantly decrease over the last 20 
years, and still develops in about half of all patients un-
dergoing allogeneic HSCT  [4] . While novel transplanta-
tion techniques such as reduced-intensity conditioning 
regimens are associated with less severe acute GVHD rel-
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 Abstract 
 Background: Graft-versus-host disease (GVHD) is a major 
complication after allogeneic hematopoietic stem cell trans-
plantation (HSCT) and skin is involved in acute and chronic 
disease. Immune-mediated vessel attack and subsequent 
microvessel loss have been observed in skin of patients with 
chronic GVHD.  Objectives: To test whether long-term survi-
vors (LTS) after allogeneic HSCT without cutaneous GVHD 
show signs of persistent vascular remodeling.  Methods: Mi-
crovessels in skin biopsies were investigated in a cohort of 
32 LTS with a median follow-up of 17 years (range 11–26). Five 
were currently classified as having chronic GVHD other than 
skin involvement.  Results: LTS showed no significant differ-
ence in median microvessel density and relative vessel size 
distribution pattern compared to healthy controls. Past ex-
perience of GVHD and current status of chronic GVHD other 
than skin involvement had no impact on vessel density. In 
contrast, recipients with chronic cutaneous GVHD of scle-
rotic type and patients with lichen sclerosus have significant 
microvessel loss in the upper dermis.  Conclusion: The com-
plex therapy of allogeneic HSCT had no sustained effect on 
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ative to myeloablative regimens, the incidence of acute 
GVHD has remained unchanged  [4, 5] . By comparison, 
extended eligibility criteria for patients undergoing trans-
plantation (e.g. increased upper age limit), increased hu-
man leukocyte antigen disparity, prolonged initial sur-
vival due to reduction of early mortality as a consequence 
of better prophylaxis and treatment strategies of immedi-
ate complications of transplantation (e.g. acute GVHD 
and infections), and increased use of peripheral blood 
stem cells have increased the risk for chronic GVHD 
 [6] .
 Cutaneous GVHD is divided into an acute and chron-
ic form and has recently been reviewed by our group  [7] . 
Acute GVHD is pathophysiologically well understood 
and initiation and maintenance involves various host 
and recipient immunocompetent cells as well as noncel-
lular molecules  [8, 9] . In contrast, the pathogenesis of 
chronic GVHD is more complex and thought to be pri-
marily an immune-mediated process that mostly in-
volves alloreactive CD4+ and CD8+ T cells as main ef-
fectors  [10] . As a hallmark feature, chronic GVHD may 
present with clinical and laboratory findings that resem-
ble various autoimmune disorders, e.g. bronchiolitis ob-
literans, Sjögren’s syndrome, immune cytopenias, and 
cutaneous sclerosis, suggesting that dysfunctional hu-
moral immunity might be involved in the pathogenesis 
as well  [11–13] .
 It has previously been shown that patients with active 
chronic GVHD have significantly reduced microvessels 
in skin compared to healthy controls  [14] . It has been hy-
pothesized that antiendothelial immune attack and sub-
sequent vessel loss in these patients is the result of allore-
active antiendothelial cytotoxic T cells. However, in this 
former study we had no access to skin biopsies from long-
term survivors (LTS) free of cutaneous GVHD. There-
fore, we could not rule out that the process of allogeneic 
HSCT itself would affect microvascular remodeling in 
the skin.
 In this present study, we investigated skin biopsies of 
a homogeneous population of 32 recipients more than 10 
years after allogeneic HSCT who lacked any clinical signs 
of cutaneous GVHD at the time of biopsy. The main aim 
of our investigations was to examine the cutaneous mi-
crovasculature in LTS of allogeneic HSCT, to determine 
whether in these individuals vascular remodeling (vessel 
size distribution pattern) or restitutio ad integrum (com-
plete reconstitution of vessel quantity and normal vessel 
size distribution pattern) of the cutaneous microvascular 
network occurs, and to eventually establish microvascu-
lar criteria for subclinical GVHD. 
 Patients and Methods 
 Patients 
 We investigated skin biopsies of 32 allogeneic stem cell trans-
plant recipients more than 10 years after myeloablative bone 
marrow transplantation.  Table 1  summarizes the  key data of the 
study population (LTS). Roughly 2/3 of our LTS previously ex-
perienced acute GVHD demonstrating classical erythematous 
rash that resolved within days to a few weeks after standard 
treatment (systemic glucocorticoids). LTS who previously expe-
rienced limited chronic GVHD had localized sclerodermatous 
skin disease, while patients with extensive chronic GVHD had 
a generalized cutaneous involvement including fibrosing forms. 
Our study was a cooperative project related to the single-center 
prospective study in Basel entitled ‘Altered immunity in long-
term survivors after allogeneic hematopoietic stem cell trans-
plantation as compared with their respective donors’. All 44 re-
cipients and their respective donors gave written informed con-
sent to the protocol that was approved by the local institutional 
ethics review board. For the cooperative project, the ethics re-
view board only allowed to take skin biopsies from recipients but 
not from their respective donors. Of the 44 recipients, 4 refused 
skin biopsy and the remaining 40 patients gave written informed 
consent. Of those, 32  samples were considered representative 
and could be further investigated [32 for confocal microscopy 
and 28 for immunohistochemistry (IHC)]. Eight samples (for 
confocal microscopy) and 12 samples (for IHC) could not be 
processed for various technical reasons and were independently 
qualified as insufficient by two of us (P.H., E.K.). Formalin-
fixed, paraffin-embedded 6-mm punch biopsies were taken 
from normal-appearing and sun-protected skin, such as on the 
back, thigh, abdomen, upper arm or gluteal. At the time of bi-
opsy, all recipients of our cohort did not show any clinical signs 
of cutaneous GVHD. 
 Table 1 summarizes all important data of the other investi-
gated groups apart from LTS, i.e. patients with chronic sclerotic 
GVHD and those who never had allogeneic HSCT (healthy con-
trols, patients with lichen sclerosus, and patients with morphea). 
Except for healthy controls, 4-mm punch biopsies of the lateral 
borders of lesional skin were taken exclusively for diagnostic pur-
poses after patient’s consent and before the start of this prospec-
tive study. All patients with chronic cutaneous GVHD of scle-
rotic type presented homogeneously with hallmark clinical and 
histopathological features of chronic sclerotic GVHD of skin. Pa-
tients with morphea and lichen sclerosus presented the classical 
clinical and histopathological characteristics of the respective 
disease. Normal-appearing skin of healthy controls was taken af-
ter patient’s consent from the edges of spindle excisions for cos-
metically distracting and required removals of benign fibromas 
and papillomatous melanocytic nevi.
 Slide Preparation 
 We embedded formalin-fixed skin biopsy samples in paraffin 
and cut 5-mm-thick sections. Paraffin was removed by xylol and 
treatment with 100, 96, and 70% ethanol. After rinsing the slides 
in phosphate-buffered saline (PBS; pH 7.4), we demasked the an-
tigens in 10 mmol/l citrate buffer (pH 6) in a steam presser cham-
ber for 2 min. The slides were washed again with PBS. 
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 Immunohistochemistry 
 Before IHC, slides were preincubated with 3% hydrogen per-
oxide in 50% methanol. Vascular endothelial cells were detected 
with antibody against von Willebrand factor (vWF). We incu-
bated slides with rabbit anti-vWF (1: 600, DAKO) and a peroxi-
dase-conjugated goat anti-rabbit antibody (EnVision System HRP 
rabbit, DAKO). DAB EnVision kit was used for detection (DAKO). 
Slides were analyzed with a light microscope (Leica DM 2500, 
Leica Microsystems, Wetzlar, Germany) and photographed with 
a digital camera.
 Immunofluorescence  
 Nonspecific binding sites were blocked with 3% fat-free dry 
milk in PBS for 30 min at room temperature. Vascular endothe-
lial cells were detected with anti-vWF antibody (1: 200, DAKO) for 
1 h at room temperature. Slides were rinsed with PBS and incu-
bated with cyanine 5 (Cy5)-conjugated donkey anti-rabbit anti-
body (1: 800, Jackson ImmunoResearch, West Grove, Pa., USA) 
for 30 min at room temperature. The slides were then rinsed again 
with PBS and mounted under glass with hydrophilic embedding 
medium (Faramount, DAKO). Immunofluorescence (IF) was de-
tected with a confocal microscope (Zeiss, Jena, Germany).
 Quantitative Morphometric Analysis of Microvessel Density 
 For each patient, one microscopy slide containing a represen-
tative paraffin section from the skin biopsy was analyzed. For 
IHC slides, one image per slide was taken. In the superficial der-
mis (a subepidermal region 150–200 mm deep), we determined 
the area to be analyzed and then counted the number of vessels 
and measured the diameter of vascular profiles lined by endothe-
Table 1. Key data of all investigated groups
LTS Chronic sclerotic GVHD
Number of patients 32 5
Sex (m/f) 19 (59)/13 (41) 5 (100)/0
Median age at transplantation, years 25 (5–50) 47.5 (39–56)
Median time interval after HSCT, years 17 (11–26) 2 (1–5)
Skin status at follow-up examination
Clinical assessment normal 100% sclerodermoid 100%
Histological assessment normal 100% sclerodermoid 100%
Diagnosis
Aplastic anemia 4 (12) –
Acute myeloid leukemia 12 (38) 1 (20)
Chronic myeloid leukemia 9 (28) –
Acute lymphoblastic leukemia 4 (13) 2 (40)
Non-Hodgkin lymphoma 2 (6) –
Chronic lymphocytic leukemia 1 (3) 2 (40)
Myelodysplastic syndrome 1 (3) –
Total body irradiation (yes/no) 27 (84)/5 (16) 5 (100)
Source of stem cells: bone marrow 100% 100%
Median nucleated cell dose for transplantation (!108/kg) 3.77 (0.59–16.6) 6.43 (3.58–13.75)
Donor type: matched sibling 100% 100%
Previous experience of acute GVHD
None or grade I/grade II–IV 15 (47)/17 (53)1 1 (20)/4 (80)
Previous experience of chronic GVHD
None/yes, limited/extensive 17 (53)/15 (47), 10/5 3 (60)/2 (40)
Current status of chronic GVHD
None/limited/extensive 27 (84.5)/2 (6)/3 (9.5) n.a.
Healthy controls Morphea Lichen sclerosus
Number of samples 6 5 5
Skin status
Clinical assessment normal skin 100% morphea 100% lichen scl. 100%
Histological assessment normal skin 100% morphea 100% lichen scl. 100%
Sex (m/f) 4 (67)/2 (33) 2 (40)/3 (60) 1 (20)/4 (80)
Median age, years 46 (26–76) 43 (15–70) 59 (14–68)
Figures in parentheses indicate ranges or percentages. 1 Acute GVHD grade 0: n = 11 (34.4%); grade I: n = 4 (12.5%); grade II: n = 
13 (40.6%); grade III: n = 4 (12.5%); grade IV: n = 0 (0%).
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lial cells using image analysis software (Cell P , Olympus Soft Im-
aging Solutions, Volketswil, Switzerland). On average, 0.33 mm 2 
of the superficial dermis were examined per patient. Vessel pro-
files were categorized according to their diameter (no lumen/0–10 
mm/10–20 mm/ 1 20 mm). Total profile counts/mm 2 as well as 
profile count per category were determined. Results were calcu-
lated as median profile number/mm 2 (total profile density) and 
median profile number per category divided by median total 
count (percent of total count). For IF-stained slides, four repre-
sentative images were taken in the superficial dermis and the me-
dian of four results was calculated as representative value per 
slide. Fluorescence images were analyzed with Adobe  Photo-
shop  software. Total pixel number of the area to be analyzed was 
determined. Within this area, the number of pixels matching the 
wavelength of Cy5 ( fig. 1 , blue in the online version) was deter-
mined. Results were normalized according to the total pixel num-
ber of the corresponding area, and were calculated as median pix-
el number per total area pixel number for each patient group. 
 Antibodies 
 Rabbit anti-vWF (DAKO A0082) was used for vWF detection 
in both IHC and IF. Donkey anti-rabbit Cy5 (Jackson 711-175-
152) was used as a secondary antibody in IF.  Rabbit serum was 
used for negative controls in both applications. 
 Data Analysis and Statistics 
 Total profile number/mm 2 as well as relative vWF pixel counts 
are represented as medians. Mann-Whitney U test was performed 
for statistical significance to determine differences between pa-
tient groups and controls. Differences with p  ! 0.05 were consid-
ered significant. Comparison between the two endothelial cell 
measurement methods (profile number/mm 2 and Cy5 matching 
pixels per total pixels) was analyzed with the Spearman correla-
tion coefficient. Profile size distribution analysis (group compar-
isons) was tested for statistical significance with a   2 test. Differ-
ences with p  ! 0.05 were considered significant.
 Results 
 Chronic Sclerotic GVHD and Lichen Sclerosus Are 
Vanishing Vessel Diseases of the Upper Dermis 
 In this study, we investigated the status of microvas-
culature in skin of a large homogeneous population of 
allogeneic stem cell recipients with a median follow-up of 
17 years after transplantation. We morphometrically as-
sessed number and size categories of blood vessels de-
fined by immunohistochemical positivity for vWF with-
in the upper dermal layers (150–200 mm downward from 
basal membrane) anatomically corresponding to the 
compartment of the superficial vascular plexus in skin. 
 Figure 1 shows one representative sample of all investi-
gated disease groups, i.e. LTS (n = 32), chronic sclerotic 
GVHD (n = 5), morphea (n = 5), lichen sclerosus (n = 5) 
Healthy
controls
LTS Chronic
scl. GVHD
Morphea Lichen
sclerosus
C
o
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r v
er
si
o
n 
av
ai
la
b
le
 o
n
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e
 Fig. 1. Typical skin morphology of healthy controls and the four 
patient groups. Columns show all investigated patient groups and 
controls. Two different magnifications of hematoxylin/eosin-
stained paraffin sections are shown for each group. Upper row: 
superficial dermis, high-power view; lower row: deep dermis, 
low-power view. Morphological findings are described in the text. 
Bars = 50   m (upper row) and 500   m (lower row). 
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and nontransplanted healthy controls (n = 6). The ana-
tomical findings of the superficial ( fig. 1 , upper row) and 
deep ( fig. 1 , lower row) dermis are shown with a high- 
and low-power view, respectively. LTS and healthy con-
trols hereby present similar morphological findings with 
respect to vessel count, vessel size and collageneous ma-
trix. In contrast, chronic sclerotic GVHD reveals homog-
enization, enlargement and compactation of collagen fi-
bers of the upper and lower dermis and rarification of 
vessels particularly in the upper dermal parts. Morphea, 
an idiopathic sclerotic skin disorder with prominent 
compactation and homogenization of collagen fibers pri-
marily of deep dermal parts, discloses upper dermal ma-
trix and vessel characteristics similar to those of LTS and 
healthy controls. Lichen sclerosus, a fibrosing skin dis-
ease with compactation and homogenization of collagen 
of the uppermost parts of the dermis, demonstrates 
prominent vessel rarification in the papillary dermis 
within a sclerotic matrix. 
 Higher Interindividual Variability of Microvascular 
Density in LTS Compared to Healthy Controls 
 Two independent morphometric methods were used 
to assess microvascular density in the skin (for details, 
Healthy
control
LTS Chronic
scl. GVHD
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(2)
(4)
(3)
 Fig. 2. Quantitative assessment of microvascular density in skin 
by two different methods. Blood vessels are detected by staining 
for vWF using IHC or IF. Upper panels: blood vessel detection in 
the superficial dermis by IHC using anti-vWF antibody and visu-
alization with a horseradish peroxidase-conjugated secondary 
antibody and DAB EnVision kit (DAKO); lower panels: blood ves-
sel detection in the superficial dermis by IF using anti-vWF anti-
body and a secondary, Cy5 fluorescent antibody (blue in the on-
line version). Quantification is done by vessel profile count (upper 
panels) and by counting pixels that represent vWF expression 
(blue pixels in the online version, lower panels). The blood vessels 
are further categorized into four different size groups according 
to their diameter [upper panels: (1) black arrowhead: diameter 
 1 20   m, (2) green arrowhead: 10–20   m, (3) orange arrowhead: 
0–10   m, (4) yellow arrowhead: no lumen or sprouts]. Bars =
50   m; dotted red line: epidermis-dermis boundary. 
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see  fig. 2 and Methods).  Figure 3 indicates the microvas-
cular density determined as counted absolute number of 
vessel profiles/mm 2 ( fig. 3 a) and as vWF-positive pixel 
number per total pixel number of the area analyzed 
( fig. 3 b).
 Equal vascular densities are assessed in LTS and 
healthy controls by both independent quantification 
methods (vessels/mm 2 : 48.3 compared to 47.9, p = 0.947; 
pixels: 1,190 compared to 1,138, p = 0.719, Mann-Whit-
ney U test). This finding is independent of whether LTS 
previously experienced any GVHD or were currently 
classified as having chronic GVHD without skin involve-
ment [vessels/mm 2 : 51.9 (no GVHD) compared to 48.3 
(any previous GVHD), p = 0.872; pixels: 902 (no GVHD) 
compared to 1,248 (any GVHD), p = 0.478, Mann-Whit-
ney U test].
 Compared to healthy controls (47.9 vessels/mm 2 and 
1,138 pixels), an anticipated significant decrease in abso-
lute vessel count was found in chronic sclerotic GVHD 
(19.3 vessels/mm 2 , p = 0.038; 678 pixels, p = 0.018) and 
lichen sclerosus (20.0 vessels/mm 2 , p = 0.017; 344 pixels, 
p = 0.011). Also when compared to LTS, the two sclerotic 
disorders show a significant decrease in vessel count (p = 
0.008) and vWF pixels per total area (p = 0.044) for chron-
ic sclerotic GVHD, as well as for lichen sclerosus (p = 
0.003, vessels/mm 2 ; p = 0.006, vWF pixels). In contrast, 
morphea does not demonstrate significant changes of 
vessel density (51.6 vessels/mm 2 , p = 0.945; 854 vWF pix-
els, p = 0.361, Mann-Whitney U test). This is in accor-
dance with the anatomical matrix changes particularly of 
the lower dermis sparing the upper parts ( fig. 1 ).
 However, LTS show a broad range of microvascular 
density as compared to healthy controls by both indepen-
dent methods. This interindividual variability of micro-
vascular densities within the LTS group was further ex-
plored by analyzing the four quartile groups ( table 2 ; 
 fig. 3 a). The lowest subgroup of patients (1st quartile of 
data values) in fact shows a significant reduction in vessel 
density compared to healthy controls (p = 0.003 for ves-
sels/mm 2 , p = 0.013 for pixels, Mann-Whitney U test), 
0
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Morphea
(n = 5)
Lichen
sclerosus
(n = 5)
*
p = 0.011
p = 0.018
p = 0.044
p = 0.006
*
 Fig. 3. Microvascular density in healthy controls, LTS, chronic 
sclerotic GVHD, morphea and lichen sclerosus. Vascular endo-
thelial cells on paraffin sections were detected with anti-vWF an-
tibody and visualized with a horseradish peroxidase-conjugated 
secondary antibody and DAB EnVision kit (DAKO) ( a ) or a Cy5-
conjugated secondary antibody ( b ).  a The sum of all vessel pro-
files/mm 2 is equal in healthy controls, LTS and morphea. Patients 
with chronic sclerotic GVHD and lichen sclerosus show a signif-
icant reduction in vessel profile density compared to healthy con-
trols ( * ). Results are shown as median vessel profile density  8 1st 
and 3rd quartiles (p LTS = 0.947, p cGVHD = 0.038, p morphea = 0.945, 
p lichen sclerosus = 0.017, Mann-Whitney U test).  b In silico measure-
ments of vWF-positive areas (blue pixel numbers per area) con-
firm results shown in  a . The sum of all vWF-positive pixels per 
area is equal in healthy controls, LTS and morphea. Patients with 
chronic sclerotic GVHD and lichen sclerosus show a significantly 
lower vWF pixel count than healthy controls ( * ). Results are 
shown as median pixel counts  8 1st and 3rd quartiles (p LTS = 
0.719, p cGVHD = 0.018, p morphea = 0.361, p lichen sclerosus = 0.011, 
Mann-Whitney U test). 
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while the highest subgroup (4th quartile) demonstrates a 
significant increase in vessel density (p = 0.032 for ves-
sels/mm 2 , p = 0.042 for pixels, Mann-Whitney U test; 
data not shown). The 2nd and the 3rd quartiles are not 
different from the healthy controls. Importantly, when 
the 1st and the 4th quartiles were systematically investi-
gated for parameters such as recipients’ gender, age at 
transplantation, time interval after allogeneic HSCT, 
conditioning regimens with or without total body irra-
diation or previous or current status of GVHD ( table 2 ), 
we did not find any association between one of these 
characteristics and vessel quantity. 
 Finally, we compared the two quantification methods 
(vessel counts versus pixel measurement) by correlating 
the two data sets. As we generated in parallel one total 
vessel number/mm 2 (IHC) and one pixel value per area 
for each patient sample, we compared each pair of corre-
sponding values using the Spearman correlation analysis 
over all patient groups including healthy controls (a total 
of 50 pairs). Statistical analysis revealed a Spearman cor-
relation coefficient of 0.406 and a p value of 0.003 (data 
not shown), indicating a clear correlation between the 
two measurement methods. 
 No Microvascular Remodeling in LTS and in Chronic 
Sclerotic GVHD 
 Figure 4 a indicates the absolute vessel counts stratified 
per size category of vWF-positive detected vessels/mm 2 
by IHC in the upper dermis (150–200 mm measured from 
the basal membrane downwards). Irrespective of the size 
category of microvessels, LTS and healthy controls do not 
show any significant quantitative change in the vessel 
profile density (33.4 compared to 31.2 vessels/mm 2 , p = 
0.665). In contrast, significant decreases in the absolute 
number of vascular profiles in the smallest vessel catego-
ry (sprouts without detectable lumen) was found in 
chronic sclerotic GVHD (11.3 vessels/mm 2 , p = 0.010) 
and lichen sclerosus (12.5 vessels/mm 2 , p = 0.006) when 
compared to healthy controls (33.4 vessels/mm 2 ). Analo-
gously, when compared to LTS (31.2 vessels/mm 2 ), chron-
ic sclerotic GVHD (11.3 vessels/mm 2 , p = 0.008) as well 
as lichen sclerosus (12.5 vessels/mm 2 , p = 0.003) showed 
a significant decrease in the absolute number of vascular 
profiles in the smallest vessel category. Furthermore, 
chronic sclerotic GVHD and lichen sclerosus demon-
strate a relative but not significant increase in large mi-
crovessels ( 1 20 mm).
 By investigating the relative size distribution of mi-
crovessels per total vessel profile numbers (criteria for 
vascular remodeling),  figure 4 b demonstrates that the 
very small vessels either with no or very thin lumens (0–
10 mm) are the most prevalent vascular structures in all 
groups relative to the total profile numbers/mm 2 and 
compared to healthy controls. Importantly, and here 
shown for all vessel size categories, LTS and healthy con-
trols have a nearly identical vessel size distribution pat-
tern. 
 Taken together, the terminal vascular bed in the up-
permost skin of LTS is therefore almost identical to that 
of healthy controls in terms of the relative distribution of 
vessel size categories. Moreover, the relative size distribu-
tion of vessel profiles within one group (no lumen, 0–10, 
10–20,  1 20 mm) did not show any significant changes (  2 
test, p values are indicated in  fig. 4 ) compared to healthy 
controls in any of the four investigated groups. Particu-
larly with respect to diseases with quantitative loss of mi-
crovessels such as chronic sclerotic GVHD and lichen 
sclerosus, there is no evidence that the microvascular loss 
would occur preferentially in one vessel size category.
Table 2. Quartile analysis of microvascular density in LTS
LTS group 
quartiles 
(profile 
numbers) 
TBI
(yes/no)
Sex 
(m/f)
Mean age at 
transplantation 
(range)
Time interval 
after HSCT 
(mean years)
Experienced 
acute GVHD 
grade 
(I/II/III/IV)
Experienced 
chronic GVHD 
grade (none/
limited/extensive)
Current chronic 
GVHD grade 
(none/limited/
severe)
1 (17–28) 5/1 4/2 27 (18–34) 17.4 (11–25) 2/1/3/0/0 3/2/0 6/0/0
2 (38–48) 8/2 6/4 26 (5–50) 17.1 (14–23) 3/3/2/2/0 4/4/2 9/0/1
3 (52–63) 6/1 3/4 31 (20–44) 16.8 (12–20) 2/2/2/1/0 4/2/1 5/2/0
4 (75–103) 8/1 5/4 27 (5–44) 17.1 (11–26) 5/1/2/1/0 5/2/2 7/0/2
The LTS group of GVHD patients has been divided into 4 subgroups according to the patient’s vessel profile density; each group 
represents a quartile range. No correlation of the vessel density quartile groups with any of the observed parameters can be seen.
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 Discussion 
 In this observational study, we investigated the cur-
rent status of the cutaneous microvasculature in a large 
homogeneous cohort of hematopoietic stem cell recipi-
ents more than 10 years after transplantation. Our pri-
mary aim was to capture all information about absolute 
number of vessels in skin (criteria for reconstitution) and 
relative distribution of vessel size categories (criteria for 
remodeling) to objectify any subclinical long-term se-
quelae related to that therapy. Vascular structures were 
assessed according to immunohistochemical and IF re-
activity for vWF (for details see  fig. 2 ), a glycoprotein syn-
thesized by vascular endothelial cells and stored in the 
Weibel-Palade bodies  [15] . All recipients (LTS) revealed a 
high degree of homogeneity with respect to their condi-
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 Fig. 4. Size distribution of cutaneous microvessels in healthy con-
trols, LTS, chronic sclerotic GVHD, morphea and lichen sclero-
sus. Each vessel profile count was categorized according to its ves-
sel diameter into the size categories ‘no lumen’, ‘0–10   m’, ‘10–20 
  m’ and ‘ 1 20   m’. Patient groups are shown in different grayscale 
bars.  a Absolute vessel profile numbers per size categories. Results 
are shown as median vessel profile numbers  8 1st and 3rd quar-
tiles. Patients with chronic sclerotic GVHD and lichen sclerosus 
differ significantly from healthy controls in vessel profile num-
bers of the smallest category (‘no lumen’, p = 0.010 and 0.006, re-
spectively, Mann-Whitney U test). Both patient groups show a 
tendency of reduction in numbers of vessels of an intermediate 
size, and a tendency to increase the numbers of the largest vessels 
( 1 20   m); however, the tendency is not significant (all cases p  1 
0.05, Mann-Whitney U test). Patients with chronic sclerotic 
GVHD also differ significantly from LTS patients in the smallest 
vessel category (p = 0.008), indicating a normalization of the ves-
sel system in LTS (restitutio ad integrum).  b Vessel size distribu-
tion pattern per patient group. The vessel profile number from 
each size category ( a ) is divided by the total sum of all vessel pro-
files for each patient group. Results are shown as a percentage of 
total vessels (median percent  8 1st and 3rd quartiles). All patient 
groups demonstrate comparable vessel size distribution patterns 
(p LTS = 0.488, p cGVHD = 0.283, p morphea = 0.395, p lichen sclerosus = 
0.186,   2 test). 
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tioning and transplant procedures and did not show any 
clinical and histological signs of cutaneous GVHD at the 
time of follow-up and skin biopsy ( table 1 ). Our study was 
part of a cooperative project related to the single-center 
prospective study in Basel entitled  ‘ Altered immunity in 
long-term survivors after allogeneic hematopoietic stem 
cell transplantation as compared with their respective 
donors’. 
 Our main findings can be summarized as follows. 
First, LTS without clinical signs of chronic cutaneous 
GVHD and healthy controls demonstrate comparable 
morphological features with respect to dermal matrix 
and vascular structures ( fig. 1 ) as compared to patients 
with chronic sclerotic GVHD and lichen sclerosus  [14, 
16] . Second, quantitative assessment of microvascular 
density by two independent methods ( fig. 3 a, b) shows 
identical absolute numbers of vessel profiles in LTS and 
healthy controls. Both measurement methods thereby 
correlate with a Spearman correlation coefficient of 0.406 
(figure not shown). With respect to the increased interin-
dividual variability in vessel density of LTS as compared 
to healthy controls, and based on the subsequent quartile 
group analysis of LTS ( table 2 ), we were not able to iden-
tify any discriminating parameters within these sub-
groups such as sex and age at transplantation, condition-
ing regimens, years after transplantation, and, impor-
tantly, current or previous status of GVHD. This is 
particularly remarkable, as a significant blood vessel loss 
has been previously demonstrated in skin biopsies of
allogeneic stem cell recipients with clinical features of 
chronic GVHD  [14] and here confirmed by us ( fig. 3 ). 
Third, LTS and healthy controls do essentially demon-
strate an equal absolute vessel profile number per size 
category ( fig. 4 a) and a comparable relative vessel profile 
size distribution pattern ( fig. 4 b). These are crucial argu-
ments against persistent vascular sequelae of skin of LTS 
more than 10 years after transplantation. Furthermore, 
we did not find any correlation of the serum vWF of these 
LTS (data not shown) to any of the clinical parameters 
listed in  table 2 and their respective vascular density. It 
finally could be hypothesized that beyond previous oc-
currence or absence of GVHD, peritransplant procedures 
and diseases such as viral infections do not have a sus-
tained impact on the terminal vascular bed in skin of 
LTS. 
 Human microvasculature in normal skin and patho-
logical conditions have previously been visualized in de-
tail using laser Doppler flowmetry highlighting the mi-
croanatomical organization of the upper and lower hori-
zontal vascular plexus and the connecting vessels  [17–19] . 
Past investigations elucidated that various immune-me-
diated fibrosing skin diseases result in similar modifica-
tions of vascular structures, cellular and molecular events 
as well as matrix changes. Vertically oriented capillary 
loops originating from and terminating in the upper vas-
cular plexus were found to be transpositioned in lichen 
sclerosus from vertical to horizontal orientation toward 
the basal membrane zone  [16] . Induction of sclerosis in 
fibrosing skin diseases such as chronic sclerotic GVHD, 
morphea and lichen sclerosus has been demonstrated to 
be critically mediated by TGF-  -induced activation of fi-
broblasts with subsequent collagen production and the 
simultaneous stimulation of tissue inactivators for metal-
loproteinases and increases in platelet-derived growth 
factor-  receptor expression in fibroblasts and endothe-
lial endothelin-1 synthesis  [20, 21] .
 Our findings in LTS address further vascular aspects 
to the enhanced risk of premature cardiovascular disease 
recently demonstrated in 265 recipients of allogeneic he-
matopoietic stem cell transplants with a median follow-
up of 9 years  [22] . Though these late vascular events have 
not been observed in a patient cohort comparable to our 
homogeneous group of LTS, a relevant number of regis-
tered arterial episodes in these patients such as stroke, 
coronary heart disease, or peripheral arterial disease have 
been observed many years after transplantation with 
well-defined risk factors for endothelial damage such to-
tal body irradiation  [23] or GVHD  [14] . Essentially, the 
terminal vascular bed in skin comprises mainly capillar-
ies, postcapillary venules, and few arterioles, but lack 
larger arteries. Hypothetically, micro- and macrovascu-
lar structures biologically behave differently after acute 
and/or chronic damage and might have unequal capa-
bilities to recover.
 In summary, in this study we demonstrated the com-
plete remodeling and partial reconstitution of the termi-
nal vascular bed in skin of a homogeneous cohort of LTS 
more than 10 years after allogeneic HSCT and irrespec-
tive of the former occurrence of GVHD involving skin. It 
can be hypothesized that peritransplant procedures such 
as total body irradiation, chemotherapy, GVHD, drug re-
actions or infections do not have a sustained impact on 
the ability of the skin to recover a complete microvascu-
lare network many years after allogeneic HSCT.
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